Education
About Us
Working with TipRanks
Follow Us
Ironwood Pharma (IRWD)
NASDAQ:IRWD
Earnings Data
Report Date
Apr 30, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
0.25Last Year’s EPS
-0.23Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call balanced meaningful commercial and clinical progress with clear financial targets and a path to deleveraging. Highlights include strong demand growth for LINZESS (11% prescription growth, 8% new-to-brand growth), a new pediatric indication, reiterated 2026 guidance with >30% LINZESS net sales growth expected, and advancing aproglutide into an FDA-aligned confirmatory Phase III (STARS II) with encouraging prior efficacy and extension data. Key negatives are net price erosion (full-year LINZESS net sales down 6% YoY), Q4 rebate/timing-driven volatility, the FDA requirement for a confirmatory trial (adding time and cost), potential competitive pressure (including a possible GATTEX generic), and a projected >30% increase in Medicaid mix for 2026. Overall, positives (strong guidance, clinical progress, improved adjusted EBITDA outlook and disciplined cost management) outweigh the lowlights, though risks remain around pricing, payer mix, and the need to successfully execute STARS II.Company Guidance
LINZESS Full-Year Net Sales and Demand Growth
LINZESS U.S. net sales for full-year 2025 were $865 million, supported by 11% prescription demand growth and 8% new-to-brand volume growth year over year. The brand surpassed ~5.7 million unique patients treated since launch and finished 2025 with roughly 45% market share.
Regulatory and Label Expansion for LINZESS
FDA approval in November 2025 expanded LINZESS' indication to treat IBS-C in patients 7 years of age and older, making it the first and only prescription drug approved for IBS-C in patients aged 7–17.
2026 Financial Guidance and Outlook
Company reiterated 2026 guidance: LINZESS U.S. net sales expected between $1.125 billion and $1.175 billion (greater than a 30% increase year over year). Ironwood revenue guidance of $450 million–$475 million and an expectation of greater than $300 million in adjusted EBITDA for 2026.
2025 Profitability and Cash Generation
Delivered $138 million in adjusted EBITDA for 2025 and generated $127 million in cash flows from operations. Management emphasized disciplined expense management, including a $61 million reduction in operating expenses year over year, and ended the year with cash and cash equivalents reported at $215 million.
Aproglutide Clinical Progress and STARS II Alignment with FDA
Company met with the FDA in Q4 2025 and aligned on a confirmatory Phase III trial (STARS II). STARS II is planned as a randomized, double-blind, placebo-controlled trial (1:1) with a primary endpoint of relative change from baseline in weekly parenteral support volume at week 24, using a 3.5 mg once-weekly dose and planned enrollment of 124 patients. Site activation is on track to begin in Q2 2026.
Strong Clinical Efficacy Signals for Aproglutide
Prior STARS Phase III and the STARS EXTEND long-term extension showed statistically significant reductions in weekly parenteral support volume and durable improvements (including cases of enteral autonomy maintained for >= 3 months), supporting confidence in aproglutide's efficacy, tolerability, and once-weekly dosing.
Commercial Opportunity for Aproglutide
Management projects greater than $700 million U.S. peak net sales for aproglutide given its clinical profile and the potential to expand GLP-2-treated patient population; company expects additional upside from potential approvals abroad.
Balance Sheet and Deleveraging Plans
Company plans to use cash flow and cash on hand to reduce total debt in 2026, including repayment of 2026 convertible notes at maturity in June, and expects to end 2026 with approximately $300 million of debt (less than 1.0x 2026 adjusted EBITDA).
IRWD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
IRWD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 25, 2026 | $3.79 | $3.36 | -11.35% |
Nov 10, 2025 | $1.92 | $2.53 | +31.77% |
Aug 07, 2025 | $0.81 | $0.88 | +9.32% |
May 07, 2025 | $0.93 | $0.79 | -14.47% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Ironwood Pharma (IRWD) report earnings?
Ironwood Pharma (IRWD) is schdueled to report earning on Apr 30, 2026, Before Open (Confirmed).
What is Ironwood Pharma (IRWD) earnings time?
Ironwood Pharma (IRWD) earnings time is at Apr 30, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is IRWD EPS forecast?
IRWD EPS forecast for the fiscal quarter 2026 (Q1) is 0.25.